Amgen results show biosimilars and IRA pricing reshaping drug spend
Amgen reported Q2 2026 revenues of $10.1B, up 10% year over year, with product sales up 9% and GAAP diluted EPS up 65% to $4.37. Non-GAAP diluted EPS rose 4% to $6.29. The company cited biosimilar launches reducing Prolia and XGEVA sales, and IRA Medicare Part D price-setting pressuring Enbrel net selling price. Amgen is advancing MariTide in Phase 3.
How this was made
The 30-second read
Why it matters
For traders, the key new decision-relevant element is that IRA price-setting is described as operational for the first time, and Amgen links it to observed net selling price declines in Enbrel.
Market read
Quantified biosimilar revenue effects plus a specific IRA mechanism now in force can change payer and investor assumptions for biologic pricing durability.
What to watch
The article does not quantify guidance or segment-level outlook, so traders may be over-weighting Q2 product declines versus management’s forward trajectory and mix effects.
Background
Amgen’s Q2 2026 update highlights two simultaneous forces reshaping US drug spend: biosimilar competition and the IRA Medicare Drug Price Negotiation Program’s Maximum Fair Prices for Part D drugs.
Ticker impact
Amgen reports Q2 2026 results and ties biosimilar-driven declines and Enbrel net selling price pressure to IRA Medicare Part D price-setting starting Jan. 1.
Likely supports a cautious bias on AMGN versus prior expectations, with upside limited until MariTide Phase 3 efficacy data de-risks the pipeline.
It provides concrete Q2 financial metrics and product-level declines (Prolia, XGEVA, Enbrel) plus a specific policy mechanism now operational, which can reset pricing assumptions for Part D biologics.
Market effects
Reinforces that biosimilar entry at scale and IRA Part D Maximum Fair Prices are now measurable drivers of biologic revenue and net selling price.
Primarily US-focused due to Medicare Part D price-setting, with potential read-through to US employer plan formulary negotiations.
Could influence global biologic pricing expectations where US policy spillovers affect payer behavior and competitive intensity.
Counterpoint
MariTide’s monthly dosing profile could become a formulary negotiation lever once Phase 3 efficacy is released, offsetting some near-term pricing pressure.
Key entities
- companyAmgen
Reports Q2 2026 revenues, EPS, and product-level biosimilar and IRA-related pricing impacts; advances MariTide in Phase 3.
- policyInflation Reduction Act (IRA) Medicare Drug Price Negotiation Program
Sets Maximum Fair Prices for ten high-expenditure Part D drugs in 2026, described as operational starting Jan. 1.
- pipeline_programMariTide
Monthly-dosed antibody-peptide conjugate targeting GLP-1R and GIPR, in multiple Phase 3 studies without released efficacy data.
